Golo Ahlenstiel

A serum protein–to–bilirubin ratio predicts immune-mediated hepatotoxicity in lung cancer patients treated with immune-checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) have transformed outcomes for patients with advanced non-small cell lung cancer (NSCLC) but are associated with immune-related adverse events, including hepatotoxicity. Immune-mediated liver injury can necessitate treatment interruption and imm...